SITE003-0043

SITE003 (CAN) › SITE003-0043

SITE003-0043

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2025-10-23

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 152); relationship: NOT RELATED

mild assessed

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-08-04 (study day 96); relationship: NOT RELATED

severe assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 15); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.